BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 11772129)

  • 41. [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
    Johannsen M; Wilke K; Schnorr D; Loening SA
    Urologe A; 2004 Feb; 43(2):160-7. PubMed ID: 14991117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Castrate-resistant prostate cancer: therapeutic strategies.
    Harzstark AL; Small EJ
    Expert Opin Pharmacother; 2010 Apr; 11(6):937-45. PubMed ID: 20307219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging drugs for prostate cancer.
    Siddiqui K; Klotz LH
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):455-70. PubMed ID: 19650748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hormone refractory prostate cancer: Management and advances.
    Sonpavde G; Hutson TE; Berry WR
    Cancer Treat Rev; 2006 Apr; 32(2):90-100. PubMed ID: 16458434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Angiogenesis-targeted therapies in prostate cancer.
    Lara PN; Twardowski P; Quinn DI
    Clin Prostate Cancer; 2004 Dec; 3(3):165-73. PubMed ID: 15636683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update in the management of patients with hormone-refractory prostate cancer.
    Moore CN; George DJ
    Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New approaches in hormone refractory prostate cancer.
    Sonpavde G; Hutson TE
    Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemotherapy and its evolving role in the management of advanced prostate cancer.
    Schweizer MT; Antonarakis ES
    Asian J Androl; 2014; 16(3):334-40. PubMed ID: 24435058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of chemotherapy in advanced prostate cancer.
    Ernst DS
    Can J Urol; 2002 Jun; 9 Suppl 1():21-5. PubMed ID: 12121591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hormone-refractory prostate cancer: where are we going?
    Di Lorenzo G; Autorino R; Figg WD; De Placido S
    Drugs; 2007; 67(8):1109-24. PubMed ID: 17521214
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overcoming castration resistance in prostate cancer.
    Tsao CK; Small AC; Galsky MD; Oh WK
    Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment options for hormone-refractory prostate cancer].
    Heidenreich A; Ohlmann CH
    Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
    Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
    Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Update on castrate-resistant prostate cancer: 2010.
    Lassi K; Dawson NA
    Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of hormone refractory prostate cancer.
    Knox JJ; Moore MJ
    Semin Urol Oncol; 2001 Aug; 19(3):202-11. PubMed ID: 11561988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.